Tag: 10/2/21

Categories : Cardiovascular Disease GenderTags : Leave a comment

Heart Attack Deaths are Increasing in Young Women

On By ModernMedia

Fatal heart attacks are increasing among young women in the US, a study has found.

The increase has reversed a trend from 1999 to 2010 of falling heart disease deaths in young women. Cancer deaths meanwhile have been consistently falling over the period 2010 to 2018. 

“Young women in the US are becoming less healthy, which is now reversing prior improvements in heart disease deaths,” said senior author Dr Erin Michos, Johns Hopkins University School of Medicine. “With worsening epidemics of diabetes and obesity across developed countries, our findings are a warning sign that we need to pay more attention to the health of young women.”

“Women frequently put others’ health and needs before their own, often caring for children and parents and working full-time,” continued Dr Michos. “But if they have a fatal heart attack, they won’t be there for loved ones. Women must prioritise their own health, especially since heart disease is largely preventable.”

From 1999 to 2018, the respective age-adjusted mortality rates for cancer and heart disease were 52.6 and 24.0 per 100 000. Ischaemic heart disease (56%) was the most common cause of heart disease death. Respiratory tract/lung cancer (23%) was the leading cause of cancer death.

Across the 19 year study period, age-adjusted mortality rates decreased for both cancer and heart disease. However, while cancer death rates experienced a consistent decline, heart disease death rates initially fell and then increased between 2010 and 2018. This resulted in the absolute mortality gap between cancer and heart disease significantly decreasing from 32.7 to 23.0 per 100 000 per year.

The authors urged “extreme public health measures” should be taken, stressing that most heart disease was preventable, and urgent action was needed to reverse this upward trend.
“There is a misconception that women are not at risk for heart disease before the menopause, yet one-third of their cardiovascular problems occur before 65,” said Dr Michos. “Studies of young heart attack patients show that compared to men, women were less likely than to have been told they were at risk for heart disease before the attack and less often received stents and medications.”

“Most heart disease can be avoided with a healthy balanced diet, physical activity, not smoking, and maintaining healthy blood pressure, blood glucose, cholesterol level, and body weight. Just because a woman is before menopause does not mean she is not at risk. Unfortunately, the first attack can be fatal, so we need to do better with prevention,” she concluded.

Source: Medical-News.Net

Journal information: Khan, S. U., et al. (2021) A comparative analysis of premature heart disease- and cancer-related mortality in women in the USA, 1999–2018. European Heart Journal – Quality of Care and Clinical Outcomes. doi.org/10.1093/ehjqcco/qcaa099.

Categories : CancerTags : Leave a comment

Tumour Weakened against Radiation by Tweaking a Certain Protein

On By ModernMedia

The vulnerability of specific tissues to ionising radiation has been linked to the time-varying levels of a tumour-suppressing protein, opening new avenues for cancer combination therapy.

The ability for cells to survive radiation damage has been known to be connected to p53, but tissues with vastly different levels of p53 have been shown to have great differences in sensitivity. In the face of this apparent paradox, researchers from Blavatnik Institute at Harvard Medical School, Massachusetts General Hospital, and the Novartis Institutes for BioMedical Research investigated the behaviour of p53 in irradiated tissues.

“Dynamics matter. How things change over time matters,” said co-corresponding author Galit Lahav, the Novartis Professor of Systems Biology at HMS. “Our ability to understand biology is limited when we only look at snapshots. By seeing how things evolve temporally, we gain much richer information that can be critical for dissecting diseases and creating new therapies.”

Ionising radiation randomly damages a cell’s molecular machinery, causing it to initiate cell death if it is too serious. The arbitrator of cellular suicide is p53, which is also involved in tumour suppression. 

The findings opened new avenues for combination cancer therapies, as they discovered that administering a drug that blocks p53 levels from oscillating resulted in tumours in mice being more susceptible to radiation. 
Administering to the mice an experimental anti-cancer drug that inhibits MDM2, a protein which degrades p53, they forced p53 to stay elevated. The large intestine, which is normally radiation resistant, showed increased vulnerability.

Testing out this enhanced vulnerability on human tumours transplanted into mice, a significant tumour shrinkage was seen following radiation and then MDM2 inhibitor administration.

Co-corresponding author Galit Lahav, Novartis Professor of Systems Biology, Harvard Medical School explained: “By irradiating first, we force the cancer cells to activate p53, and by adding MDM2 inhibitor on top of that, we can keep p53 active longer. This combination has a much stronger effect than either alone.”

The findings showed the importance of understanding the role of p53 in cancer, the dynamic nature of which is not being looked at in studies testing MDM2. More research into the biological pathways of p53 is called for. 
“For a lab studying p53, cancer is always a major motivation. Our goal is to acquire knowledge to help develop better and more efficient therapies,” Lahav said. “Understanding how p53 behaves over time in different conditions is a critical piece of the puzzle.”

Source: News-Medical.Net

Journal information: Stewart-Ornstein, J., et al. (2021) p53 dynamics vary between tissues and are linked with radiation sensitivity. Nature Communications.doi.org/10.1038/s41467-021-21145-z

Categories : Cancer Immune SystemTags : Leave a comment

Immune Cells in Prostate Tumours Boost Survival with Immunotherapy

On By ModernMedia

A new Northwestern Medicine study discovered the reason why black men are more likely to survive prostate cancer when given immunotherapy. 

Black men die more often from prostate cancer, yet are more likely to respond to immunotherapy. The increased presence of a type of immune cell in the tumours of black men appears to be related to their increased odds of survival with immunotherapy. The findings will be published on February 10 in Nature Communications.

A research team by Dr Edward Schaeffer, chair of urology at Northwestern University Feinberg School of Medicine and Northwestern Medicine, found that men who survive prostate cancer with immunotherapy have been found to have more plasma cells. Plasma cells are a type of specially differentiated B cell, which secrete antibodies and play a key role in the adaptive immune response.

“If a man’s prostate cancer has numerous plasma cells, we found he had improved cancer survival,” Schaeffer said. “Our study suggests plasma cells are important in the body’s response to cancer.”

Recent studies have shown that black men with advanced prostate cancer have on average better response to immunotherapy than white men. However, there has been no way to determine which individuals would have a better response, regardless of race.

Schaeffer’s team went through the genomics of 1300 tumour samples classified to genetic ancestry or self-identified race, and found more plasma cells in the tumours of black men than those of white men. However, the finding was not unique to black men alone, as elevated plasma cells in all men raised the odds of cancer-free survival after surgery.

“The finding comes at a time as researchers are discovering plasma cells may play a greater role in cancer immunotherapy than previously thought,” said first author Dr. Adam Weiner, a Northwestern Medicine urology resident. “Testing for plasma cells in prostate cancer may help identify men who will benefit from immune-based treatments.”

Source: Medical Xpress

Categories : Medical Research & TechnologyTags : Leave a comment

New Biomaterials Could Boost Vaccines or Self-sterilise PPE

On By ModernMedia

Researchers from the Indian Institute of Science describe two technologies currently being researched that could be of great benefit in fighting viruses.

These technologies could enhance the effectiveness of vaccines, and also make surfaces destructive to viruses.

“It is important not just in terms of COVID,” explained author Kaushik Chatterjee. “We’ve seen SARS, and MERS, and Ebola, and a lot of other viral infections that have come and gone. COVID has, of course, taken a different turn altogether. Here, we wanted to see how biomaterials could be useful.”

The technologies combine the field of biomaterials, which are designed to interact with biological systems, along with nanotechnology, where structures are engineered on a tiny scale. Biomaterials have been used for dental implants and joint replacements, while nanotechnology has been harnessed for drug delivery systems.

One application the authors describe is the combination of nanotechnology and biomaterial could be used to prepare the immune system to recognise vaccine antigens.

“It is a means of stimulating the immune cells which produce antibodies during the vaccination,” explained author Sushma Kumari. “It is like a helper, like priming the cells. Now, the moment they see the protein, the cells are more responsive to it and would be secreting more antibodies.”

Another technology application is surfaces that disinfect themselves. By putting an electrical charge onto the surfaces, they could be made into a hostile coating that damages or destroys virus particles when they fall onto them. These surfaces could be used for PPEs and high-touch items such as doorknobs. This would save considerable time, effort and expense in regularly disinfecting surfaces with chemicals or UV irradiation. A similar existing technology is the use of silver nanoparticles as antibacterial medical device coatings.

This technology is very much in its early stages, the researchers stressed. Research needs to be done on which biomaterials are suitable for fighting viruses, and the solution for one disease may not be applicable to another.

Source: Medical Xpress

Journal information: “Biomaterials-based formulations and surfaces to combat viral infectious diseases” APL Bioengineering, DOI: 10.1063/5.0029486

Categories : Ageing COVID General InterestTags : Leave a comment

Europe’s Oldest Living Person, 116, Survives COVID

On By ModernMedia

A 116 year old French nun who is Europe’s oldest living person has survived COVID after testing positive.

French nun Sister Andrée had tested positive for COVID in her retirement home in Toulon, but had remained symptom-free. Most of the 88 residents at the home contracted the virus, 10 of whom died. 

Sister Andrée, who is blind and in a wheelchair, said that her main complaint was the solitude necessitated by being confined to her room.
“I didn’t even realise I had it,” she told Var-Matin newspaper:

David Tavella, a spokesperson for the nursing home, told the newspaper that she had no fear of the virus.

“She didn’t ask me about her health but about her routine. She wanted to know for example if the meal and bed times were going to change. She showed no fear of the illness, in fact she was more worried about the other residents,” Mr Tavella said.

When asked by France’s BFM Television if she had been scared of having COVID, she responded: “No, I wasn’t scared because I wasn’t scared to die … I’m happy to be with you, but I would wish to be somewhere else – join my big brother and my grandfather and my grandmother.”

In addition to being Europest oldest living person, she is also the world’s second oldest living person. The oldest living person in the world is Kane Tanaka in Japan, who turned 118 on January 2. Having lived through the First World War as a child, Sister Andrée will turn 117 on Thursday.

Source: The Guardian

Categories : COVIDTags : Leave a comment

Wrong Syringes in Japan Will Waste Millions of Vaccine Doses

On By ModernMedia

When it begins inoculations, Japan will lose millions of vaccine doses because of a lack of the ‘low dead space’ syringes needed to extract the maximum number doses from each vial.

Japan had ordered 144 million doses of the Pfizer vaccine on the assumption that each vial equated to six doses. Low dead space syringes leave less vaccine in the syringe after injection, especially around the base of the needle, and result in minimal wastage. However, since low dead space syringes are in short supply in that country, regular syringes will have to be used which can only withdraw enough vaccine for five doses. This will result in the wastage of up to 24 million doses of vaccine.

“The syringes used in Japan can only draw five doses,” health minister Norihisa Tamura said, quoted by the Kyodo news agency. “We will use all the syringes we have that can draw six doses, but it will, of course, not be enough as more shots are administered.”

In large-scale vaccination programmes, the wasted vaccine in each vial becomes an issue. Skill is a factor in preserving the vaccine, but the amount of dead space in a syringe and the achievable accuracy also has a significant effect. One study showed that the amount that can be withdrawn from each vial can vary by as much 42% depending on the type of syringe used.
The US and EU have also reported shortages of low dead space syringes, and this may result in competition and supply shortages.

Japan is set to begin the first round of inoculations with 10 000 to 20 000 healthcare workers, and from there giving priority to other healthcare workers and vulnerable individuals. Inoculations for those aged 16 to 59 are not expected to begin until July.

Source: The Guardian